Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
DETECTION OF MINIMAL RESIDUAL DISEASE IN FOLLICULAR LYMPHOMAS USING PCR - VALUE OF CLONOSPECIFIC PROBES
Autore:
ALSAATI T; GALOIN S; RODA D; HUYNH A; ATTAL M; DELSOL G;
Indirizzi:
CHU PURPAN,ANAT PATHOL LAB,AVE GRANDE BRETAGNE F-31300 TOULOUSE FRANCE CHU PURPAN,UPCM,CNRS F-31300 TOULOUSE FRANCE CHU PURPAN,HEMATOL SERV TOULOUSE FRANCE
Titolo Testata:
Bulletin du cancer
fascicolo: 10, volume: 85, anno: 1998,
pagine: 847 - 854
SICI:
0007-4551(1998)85:10<847:DOMRDI>2.0.ZU;2-9
Fonte:
ISI
Lingua:
FRE
Soggetto:
POLYMERASE CHAIN-REACTION; B-CELL LYMPHOMA; BONE-MARROW TRANSPLANTATION; NON-HODGKINS-LYMPHOMA; CHROMOSOMAL TRANSLOCATION T(14-18); BREAKPOINT-CLUSTER REGION; MALIGNANT-LYMPHOMAS; GENE REARRANGEMENT; DNA; BCL-2;
Keywords:
FOLLICULAR LYMPHOMA; MINIMAL RESIDUAL DISEASE (MRD); T(14-18)(Q32-Q21) TRANSLOCATION; IGH REARRANGEMENT; CLONOSPECIFIC PROBES; CLONOSPECIFIC PCR (CS-PCR);
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
64
Recensione:
Indirizzi per estratti:
Citazione:
T. Alsaati et al., "DETECTION OF MINIMAL RESIDUAL DISEASE IN FOLLICULAR LYMPHOMAS USING PCR - VALUE OF CLONOSPECIFIC PROBES", Bulletin du cancer, 85(10), 1998, pp. 847-854

Abstract

Follicular lymphoma constitutes 30-40% of non-Hodgkin's lymphomas. Most patients have widespread disease at diagnosis. The clinical course is generally indolent, and it is not usually curable With available treatment The source of relapse in patients who achieve complete clinical remission is residual neoplastic cell that are present below the limits of detection wing standard techniques. With the development of PCRtechnology, the presence of these residual malignant cells [Minimal Residual Disease (MRD)] has been demonstrated clearly. Recently, an association of high-dose chemotherapy with autologous bone marrow or peripheral blood progenitor cell autograft appeared promising in the treatment of these lymphomas. In the search of clonal markers for the detection of MRD in follicular lymphomas, two strategies can be used. In the cases associated with the t(14;18)(q32;q21) chromosomal translocation, the bcl-2/J(H) junctional regions are amplified by PCR in similar or equal to 50% of cases and then sequenced in order to synthesize an anti-junction oligonucleotide probe specific for each patient's malignant clone (clonospecific probe). In the cases negative for this translocation, an alternative strategy consists in the amplification of immunoglobulin high chain (IgH) gene rearrangement (similar or equal to 75%of cases). The present review highlights the value of molecular markers such as bcl-2/J(H) and V-H/J(H) rearrangements to follow the neoplastic clone and to detect MRD in patients with follicular lymphomas.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/11/20 alle ore 11:27:32